The pandemic within: tackling brain vulnerability in COVID19 at high resolution: NEUROCOV

Grant number: 101057775

Grant search

Key facts

  • Disease

    Severe Acute Respiratory Syndrome (SARS)
  • Start & end year

    2022
    2027
  • Known Financial Commitments (USD)

    $8,384,036
  • Funder

    European Commission
  • Principal Investigator

    SCHULTZE Joachim
  • Research Location

    Germany
  • Lead Research Institution

    DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emerged with clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are the long-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID. Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of their effects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID, as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach that reaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modelling all the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectories of NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and three clinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition. We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissect the principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differential SARS-CoV-2 sensitivity. Through a substantive engagement of patients'Äô collectives and health care stakeholders, upstream integration of innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.

Publicationslinked via Europe PMC

Last Updated:43 minutes ago

View all publications at Europe PMC

Unveiling the power of high-dimensional cytometry data with cyCONDOR.

Operationalisation of post-COVID condition case definition in a comprehensive research protocol.

How do clinicians use post-COVID syndrome diagnosis? Analysis of clinical features in a Swedish COVID-19 cohort with 18 months' follow-up: a national observational cohort and matched cohort study.

No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache.